Consistent with nivolumab in advanced NPC,10 our study observed a numerically higher but not statistically significant ORR of PD-L1 TC+ patients than PD-L1 TC− patients (27.1% v 19.4%). The gene discussed is CD274; the disease is nasopharyngeal carcinoma.